- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-2-2-mer
- Ligands
- 10 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- MAN- BMA- BMA: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-[beta-D-mannopyranose-(1-3)]alpha-D-mannopyranose-(1-6)-[beta-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-BMA-BMA.3: 25 residues within 4Å:- Chain A: N.691, F.692, T.693, L.896, N.899, Q.900, Q.1045
- Chain E: G.93, Y.94
- Chain G: A.31, H.32, T.33, S.52, T.53, S.54, T.56, Y.57, K.99, G.100, S.101, L.104, S.105, D.106, N.107, D.108
10 PLIP interactions:1 interactions with chain A, 1 interactions with chain E, 8 interactions with chain G- Hydrophobic interactions: A:Q.900
- Hydrogen bonds: E:Y.94, G:H.32, G:T.33, G:T.33, G:T.33, G:K.99, G:S.105, G:D.108, G:D.108
- 1 x NAG- NAG- BMA- MAN- BMA: alpha-D-mannopyranose-(1-3)-[beta-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 31 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.14: 2 residues within 4Å:- Chain A: S.34, N.35
Ligand excluded by PLIPNAG.15: 6 residues within 4Å:- Chain A: N.96, A.97, T.98, N.99, V.101, K.103
Ligand excluded by PLIPNAG.16: 4 residues within 4Å:- Chain A: P.304, N.305, P.553, Q.554
Ligand excluded by PLIPNAG.17: 7 residues within 4Å:- Chain A: F.312, G.313, F.316, N.317, V.341, L.342, F.348
Ligand excluded by PLIPNAG.18: 4 residues within 4Å:- Chain A: A.680, E.1046, K.1047, N.1048
Ligand excluded by PLIPNAG.19: 2 residues within 4Å:- Chain A: E.106, N.139
Ligand excluded by PLIPNAG.20: 2 residues within 4Å:- Chain A: H.629, N.631
Ligand excluded by PLIPNAG.21: 3 residues within 4Å:- Chain A: N.254, E.255, N.256
Ligand excluded by PLIPNAG.22: 2 residues within 4Å:- Chain A: N.590, T.592
Ligand excluded by PLIPNAG.23: 2 residues within 4Å:- Chain A: N.683, N.684
Ligand excluded by PLIPNAG.24: 3 residues within 4Å:- Chain B: N.254, E.255, N.256
Ligand excluded by PLIPNAG.25: 4 residues within 4Å:- Chain B: P.304, N.305, P.553, Q.554
Ligand excluded by PLIPNAG.26: 6 residues within 4Å:- Chain B: F.312, G.313, F.316, N.317, V.341, L.342
Ligand excluded by PLIPNAG.27: 1 residues within 4Å:- Chain B: N.577
Ligand excluded by PLIPNAG.28: 2 residues within 4Å:- Chain B: N.590, Q.618
Ligand excluded by PLIPNAG.29: 2 residues within 4Å:- Chain B: H.629, N.631
Ligand excluded by PLIPNAG.30: 3 residues within 4Å:- Chain B: N.683, I.1104, G.1105
Ligand excluded by PLIPNAG.31: 4 residues within 4Å:- Chain B: A.680, E.1046, K.1047, N.1048
Ligand excluded by PLIPNAG.32: 2 residues within 4Å:- Chain B: E.106, N.139
Ligand excluded by PLIPNAG.33: 1 residues within 4Å:- Chain B: N.35
Ligand excluded by PLIPNAG.34: 4 residues within 4Å:- Chain B: N.96, A.97, N.99, K.103
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain C: H.629, N.631
Ligand excluded by PLIPNAG.36: 5 residues within 4Å:- Chain A: Q.869
- Chain C: A.680, E.1046, K.1047, N.1048
Ligand excluded by PLIPNAG.37: 2 residues within 4Å:- Chain C: E.106, N.139
Ligand excluded by PLIPNAG.38: 1 residues within 4Å:- Chain C: N.35
Ligand excluded by PLIPNAG.39: 4 residues within 4Å:- Chain C: N.96, A.97, N.99, K.103
Ligand excluded by PLIPNAG.40: 3 residues within 4Å:- Chain C: N.254, E.255, N.256
Ligand excluded by PLIPNAG.41: 4 residues within 4Å:- Chain C: P.304, N.305, P.553, Q.554
Ligand excluded by PLIPNAG.42: 6 residues within 4Å:- Chain C: F.312, G.313, F.316, N.317, V.341, L.342
Ligand excluded by PLIPNAG.43: 1 residues within 4Å:- Chain C: N.577
Ligand excluded by PLIPNAG.44: 2 residues within 4Å:- Chain C: N.590, Q.618
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Williams, W.B. et al., Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell (2021)
- Release Date
- 2020-12-30
- Peptides
- Spike glycoprotein: ABC
2G12 heavy chain: DG
2G12 light chain: EF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
HG
ME
KF
L
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-2-2-mer
- Ligands
- 10 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- MAN- BMA- BMA: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-[beta-D-mannopyranose-(1-3)]alpha-D-mannopyranose-(1-6)-[beta-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- BMA: alpha-D-mannopyranose-(1-3)-[beta-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 31 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Williams, W.B. et al., Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell (2021)
- Release Date
- 2020-12-30
- Peptides
- Spike glycoprotein: ABC
2G12 heavy chain: DG
2G12 light chain: EF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
HG
ME
KF
L